ABL1 and chlamydia trachomatis infectious disease: The dose-dependent downregulation of mid phase-chlamydial infection by dasatinib, which can inhibit the activity of EphA2, Src, BCR-Abl, KIT and PDGFR [31,32], did not correlate well with the downregulation of the PI3K pathway (Fig 7).